date:Dec 10, 2012
va will not take over Fluxomes US sales and marketing organisation but will instead focus on working with distributors and major consumer goods companies to drive sales of the product, including in Asia. The transaction does not include Fluxomes poly-unsaturated fatty acid programme. Evolva expects to leverage its own technologies to reduce manufacturing costs and further enhance the competitive advantages of Fluxomes resveratrol.
As payment for the assets, Evolva will:
Make an upfront paymen